Company to advance its lead drug candidate, TNT009, into clinical development for Complement-mediated rare diseases

South San Francisco, CA, June 17, 2014—True North Therapeutics, a biotechnology company developing novel therapies that selectively inhibit the Complement system to treat rare d…